Heroes

What do these 6 stars have in common? They fund sea vigilantes who take down evil sea criminals.

Next up in badass things old school celebs are doing that you didn't even know about ...

What do these 6 stars have in common? They fund sea vigilantes who take down evil sea criminals.
True
Waitt Foundation

Bob Barker. Beloved host of "The Price Is Right" from 1972 to 2007...

He famously ended every show with a reminder to spay and neuter your pets because he loves animals. GIF via "The Price Is Right."


...and partial bankroller to a group of vigilantes that have been chasing down evil criminals on the high seas.

Law enforcement on the high seas is lax. And there's a LOT of money to be made from taking advantage of that. It's not uncommon for fishing ships to go rogue, fish illegally, and seriously abuse both the environment and human rights with little regard.

So the current reality is this: Bob Barker and other celebrities are putting their money into a group called Sea Shepherd Global — because if governments won't protect the seas, Sea Shepherd sure will.

With vigilante justice...

"[Sea Shepherd] describes itself as an eco-vigilante group, flies a variation of the Jolly Roger on its ships and often cites the motto, 'It takes a pirate to catch a pirate.' ... Sea Shepherd's goal was not just to protect a rapidly disappearing species of fish, its leaders said, but to show that flagrant violators of the law could be brought to justice." — Ian Urbina from The New York Times on Sea Shepherd

And boats bought by Bob Barker!

Note: This is the actual boat named "Bob Barker." I know. Shark! It looks so badass! Image by AussieLegend/Wikimedia Commons.

Recently, Sea Shepherd Global sailed Bob Barker's boat (appropriately named the Bob Barker) and trailed a boat called the Thunder, which was notorious for illegally fishing for Chilean sea bass — to the tune of $76 million in illegal sales in the past decade. The Bob Barker trailed the Thunder for over 100 days in the Arctic, and the chase ended when the Thunder sank.

"There is no way to stop it sinking." Stopped, The Thunder took its illegal evidence 2 miles down to the sea floor. The 4th Installment of The Outlaw Ocean: http://urbina.io/1KuY8Zz
A photo posted by Ian Urbina (@ian_urbina) on

It was dramatic. But that's how Sea Shepherd rolls.

So are we talking about a vigilante navy funded in part by famous people? Yes, we are.

And Bob's not the only patron. I looked into other famous folks involved in Sea Shepherd and found more than a few names I recognized! Sea Shepherd's board of advisors includes even more — Sean Penn, Linda Blair, Pierce Brosnan, and others!

Here are my favorite five:

1. Bob Barker

Image by Iaksge/Wikimedia Commons.

He bought a boat! And Sea Shepherd, the organization he bought it for, named it after him.

2. Sam Simon, co-creator of "The Simpsons"

Image by Matt Waldron/Wikimedia Commons.

Sam Simon was a famously big-hearted philanthropist. He largely funded the $2 million purchase of Sam Simon the boat, and the rest is Sea Shepherd history.


Image by Saberwyn/Wikimedia Commons.

Illegal-sea-bass, sea-chasing history.

While the Bob Barker was hot on the tail of the Thunder, the Sam Simon was helping out with fuel, supplies, and other things on the high, icy seas of Chilean sea bass territory.

3. Martin Sheen

Image by Damon D'Amato/Wikimedia Commons.

He's got a boat, too! It's mainly involved in dealing with the issue of plastic debris in the oceans. Where the government fails, President Bartlett steps in!

4. MacGyver!

Image by Themightyquill/Wikimedia Commons.

That is, Richard Dean Anderson, most famously known (to me) for playing MacGyver.

His pet cause is baby seals. He's worked with Sea Shepherd a lot to raise awareness around seal hunting.

5. Brigitte Bardot

Image by MGM/Wikimedia Commons.

She's got a Sea Shepherd boat too! It's an anti-whaling boat.


Image by AussieLegend/Wikimedia Commons.

Bardot went on a whaling trip with the founder of Sea Shepherd in 1977, and she's been involved ever since.

6. James Bond aka Sean Connery

Image via Rob Mieremet/Dutch National Archives/Wikimedia Commons.

He's on the International Advisory Board of the Sea Shepherd Conservation Society.

Welcome to 2015, where part of the ocean is kinda ruled by celebrities.

The chase of the Thunder wasn't the end. Until governments step up, Sea Shepherd Global will continue its vigilante justice on the Wild West-iest parts of the Earth's ocean.

Another pirate ship on Interpol's Most Wanted list was recently chased down by Sea Shepherd, which then got police to detain the ship in port in Thailand. Then one night, when the police weren't paying attention, the ship snuck away, back onto the high seas. *facepalm*

And until actual governments step up, the price is right ... on celebrity funded vigilante ocean justice.

And remember, no more Chilean sea bass! ;)

via KTLA 5 / YouTube

A little after 7:30 on Tuesday night, Los Angeles County Sheriffs received multiple reports about a herd of cows running through the streets of Pico Rivera, a city 11 miles southeast of Los Angeles.

This Twitter video does a perfect job of encapsulating the surprise residents felt when they saw 40 cows running through their quiet suburban neighborhood.

Keep Reading Show less
via KTLA 5 / YouTube

A little after 7:30 on Tuesday night, Los Angeles County Sheriffs received multiple reports about a herd of cows running through the streets of Pico Rivera, a city 11 miles southeast of Los Angeles.

This Twitter video does a perfect job of encapsulating the surprise residents felt when they saw 40 cows running through their quiet suburban neighborhood.

Keep Reading Show less
True

Each year, an estimated 1.8 million people in the United States are affected by cancer — most commonly cancers of the breast, lung, prostate, and blood cancers such as leukemia. While not everyone overcomes the disease, thanks to science, more people are surviving — and for longer — than ever before in history.

We asked three people whose lives have been impacted by cancer to share their stories – how their lives were changed by the disease, and how they're using that experience to change the future of cancer treatments with the hope that ultimately, in the fight against cancer, science will win. Here's what they had to say.

Celine Ryan, 55, engineer database programmer and mother of five from Detroit, MI

Photo courtesy of Celine Ryan

In September 2013, Celine Ryan woke up from a colonoscopy to some traumatic news. Her gastroenterologist showed her a picture of the cancerous mass they found during the procedure.

Ryan and her husband, Patrick, had scheduled a colonoscopy after discovering some unusual bleeding, so the suspicion she could have cancer was already there. Neither of them, however, were quite prepared for the results to be positive -- or for the treatment to begin so soon. Just two days after learning the news, Ryan had surgery to remove the tumor, part of her bladder, and 17 cancerous lymph nodes. Chemotherapy and radiation soon followed.

Ryan's treatment was rigorous – but in December 2014, she got the devastating news that the cancer, once confined to her colon, had spread to her lungs. Her prognosis, they said, was likely terminal.

But rather than give up hope, Ryan sought support from online research, fellow cancer patients and survivors, and her medical team. When she brought up immunotherapy to her oncologist, he quickly agreed it was the best course of action. Ryan's cancer, like a majority of colon and pancreatic cancers, had been caused by a defect on the gene KRAS, which can result in a very aggressive cancer that is virtually "undruggable." According to the medical literature, the relatively smooth protein structure of the KRAS gene meant that designing inhibitors to bind to surface grooves and treat the cancer has been historically difficult. Through her support systems, Ryan discovered an experimental immunotherapy trial at the National Institutes of Health (NIH) in Bethesda, MD., and called them immediately to see if she was eligible. After months of trying to determine whether she was a suitable candidate for the experimental treatment, Ryan was finally accepted.

The treatment, known as tumor-infiltrating lymphocyte therapy, or TIL, is a testament to how far modern science has evolved. With this therapy, doctors remove a tumor and harvest special immune cells that are found naturally in the tumor. Doctors then grow the cells in a lab over the next several weeks with a protein that promotes rapid TIL growth – and once the cells number into the billions, they are infused back into the patient's body to fight the cancer. On April 1, 2015, Ryan had her tumor removed at the NIH. Two months later, she went inpatient for four weeks to have the team "wash out" her immune system with chemotherapy and infuse the cells – all 148 billion of them – back into her body.

Six weeks after the infusion, Ryan and Patrick went back for a follow-up appointment – and the news they got was stunning: Not only had no new tumors developed, but the six existing tumors in her lungs had shrunk significantly. Less than a year after her cell infusion, in April 2016, the doctors told Ryan news that would have been impossible just a decade earlier: Thanks to the cell infusion, Ryan was now considered NED – no evaluable disease. Her body was cancer-free.

Ryan is still NED today and continuing annual follow-up appointments at the NIH, experiencing things she never dreamed she'd be able to live to see, such as her children's high school and college graduations. She's also donating her blood and cells to the NIH to help them research other potential cancer treatments. "It was an honor to do so," Ryan said of her experience. "I'm just thrilled, and I hope my experience can help a lot more people."

Patrice Lee, PhD, VP of Pharmacology, Toxicology and Exploratory Development at Pfizer

Photo courtesy of Patrice Lee

Patrice Lee got into scientific research in an unconventional way – through the late ocean explorer Jacques Cousteau.

Lee never met Cousteau but her dreams of working with him one day led her to pursue a career in science. Initially, Lee completed an undergraduate degree in marine biology; eventually, her interests changed and she decided to get a dual doctoral degree in physiology and toxicology at Duke University. She now works at Pfizer's R&D site in Boulder, CO (formerly Array BioPharma), leading a group of scientists who determine the safety and efficacy of new oncology drugs.

"Scientists focused on drug discovery and development in the pharmaceutical industry are deeply committed to inventing new therapies to meet unmet needs," Lee says, describing her field of work. "We're driven to achieve new medicines and vaccines as quickly as possible without sacrificing safety."

Among the drugs Lee has helped develop during her career, including cancer therapies, she says around a dozen are currently in development, while nine have received FDA approval — an incredible accomplishment as many scientists spend their careers without seeing their drug make it to market. Lee's team is particularly interested in therapies for brain metastases — something that Lee says is a largely unmet need in cancer research, and something her team is working on from a variety of angles. "Now that we've had rapid success with mRNA vaccine technology, we hope to explore what the future holds when applying this technology to cancers," Lee says.

But while evaluating potential cancer therapies is a professional passion of Lee's, it's also a mission that's deeply personal. "I'm also a breast cancer survivor," she says. "So I've been on the other side of things and have participated in a clinical trial."

However, seeing how melanoma therapies that she helped develop have affected other real-life cancer patients, she says, has been a highlight of her career. "We had one therapy that was approved for patients with BRAF-mutant metastatic melanoma," Lee recalls. "Our team in Boulder was graced by a visit from a patient that had benefited from these drugs that we developed. It was a very special moment for the entire team."

None of these therapies would be available, Lee says without rigorous science behind it: "Facts come from good science. Facts will drive the development of new drugs, and that's what will help patients."

Chiuying "Cynthia" Kuk (they/them) MS, 34, third-year medical student at Michigan State University College of Human Medicine

Photo courtesy of Cynthia Kuk

Cynthia Kuk was just 10 years old when they had a conversation that would change their life forever.

"My mother, who worked as a translator for the government at the time, had been diagnosed with breast cancer, and after her chemotherapy treatments she would get really sick," Kuk, who uses they/them pronouns, recalls. "When I asked my dad why mom was puking so much, he said it was because of the medicine she was taking that would help her get better."

Kuk's response was immediate: "That's so stupid! Why would a medicine make you feel worse instead of better? When I'm older, I want to create medicine that won't make people sick like that."

Nine years later, Kuk traveled from their native Hong Kong to the United States to do exactly that. Kuk enrolled in a small, liberal arts college for their Bachelor's degree, and then four years later started a PhD program in cancer research. Although Kuk's mother was in remission from her cancer at the time, Kuk's goal was the same as it had been as a 10-year-old watching her suffer through chemotherapy: to design a better cancer treatment, and change the landscape of cancer research forever.

Since then, Kuk's mission has changed slightly.

"My mom's cancer relapsed in 2008, and she ended up passing away about five years after that," Kuk says. "After my mom died, I started having this sense of urgency. Cancer research is such that you work for twenty years, and at the end of it you might have a fancy medication that could help people, but I wanted to help people now." With their mother still at the forefront of their mind, Kuk decided to quit their PhD program and enter medical school.

Now, Kuk plans to pursue a career in emergency medicine – not only because they are drawn to the excitement of the emergency room, but because the ER is a place where the most marginalized people tend to seek care.

"I have a special interest in the LGBTQ+ population, as I identify as queer and nonbinary," says Kuk. "A lot of people in this community and other marginalized communities access care through the ER and also tend to avoid medical care since there is a history of mistreatment and judgement from healthcare workers. How you carry yourself as a doctor, your compassion, that can make a huge difference in someone's care."

In addition to making a difference in the lives of LGBTQ+ patients, Kuk wants to make a difference in the lives of patients with cancer as well, like their mother had.

"We've diagnosed patients in the Emergency Department with cancer before," Kuk says. "I can't make cancer good news but how you deliver bad news and the compassion you show could make a world of difference to that patient and their family."

During their training, Kuk advocates for patients by delivering compassionate and inclusive care, whether they happen to have cancer or not. In addition to emphasizing their patient's pronouns and chosen names, they ask for inclusive social and sexual histories as well as using gender neutral language. In doing this, they hope to make medicine as a whole more accessible for people who have been historically pushed aside.

"I'm just one person, and I can't force everyone to respect you, if you're marginalized," Kuk says. "But I do want to push for a culture where people appreciate others who are different from them."